Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2025-12-25 @ 9:47 PM
NCT ID: NCT02370251
Description: None
Frequency Threshold: 5
Time Frame: 1 year
Study: NCT02370251
Study Brief: Compassionate Use of Omegaven in Children
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Omegaven Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm. Omegaven: Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB \<2 mg/dL) occurs. 4 None 9 52 0 52 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Elevated INR SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders None View
Elevated GGT SYSTEMATIC_ASSESSMENT Hepatobiliary disorders None View
Other Events(If Any):